More than a duologue: In-depth insights into epitranscriptomics and ferroptosis

Justin Chak Ting Cheung¹, Guangzheng Deng¹, Nathalie Wong¹, Yujuan Dong¹,²* and Simon Siu Man Ng¹*

¹Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China, ²CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China

Beyond transcription, RNA molecules are enzymatically modified to influence the biological functions of living organisms. The term “epitranscriptomics” describes the changes in RNA strands aside from altering the innate sequences. Modifications on adenosine (A) are the most widely characterized epitranscriptomic modification, including N^6^-methyladenosine (m^6^A), N^1^-methyladenosine (m^1^A), polyadenylation, and adenosine-to-inosine (A-to-I) RNA editing, and modifications on other nucleotides seem to be fewer, such as N^7^-methylguanosine (m^7^G), 5-methylcytosine (m^5^C), and pseudouridine (Ψ). These changes on the RNA strand surface, exclusively by their RNA-modifying proteins (RMPs), are reported in various biological phenomena, including programmed cell death (PCD). One necro-biological phenomenon that has been observed for long but has started to gain heed in recent years is “ferroptosis.” The phospholipid peroxidation by polyunsaturated-fatty-acid-containing-phospholipid hydroperoxyl (PLOOH) radicals destroys membrane integrity due to a series of mechanisms. The Fenton reaction, constituting the final Haber–Weiss reaction that is less recognized, collaboratively leading to the conversion of polyunsaturated fatty acid (PUFA) to PLOOH, is the etymological origin of ferroptosis. However, it is with increasing evidence that ferroptotic signaling is also intervened by epitranscriptomic modifications, although the truth is still ambiguous. We attempted to delineate some up-to-date discoveries on both epitranscriptomics and ferroptosis, bringing up the fundamentals to address any potential connection between the two. Next, we discussed whether a duologal relationship, or more, exists between the two, taking the ROS level and iron status into consideration. Lastly, we surveyed future perspectives that would favor the understanding of these topics.

KEYWORDS
ferroptosis, epitranscriptomics, iron metabolism, lipid peroxidation, reactive oxygen species
Introduction

The RNA world theory hypothesized that every living matter originated from RNA as the entity of evolutionary heredity, in lieu of DNA (Rana & Ankri, 2016). After that, a myriad of scientists have boosted our awareness of RNA through their work and established the principles underlying the Central Dogma of molecular biology. Nevertheless, beyond transcription, RNA molecules can also be enzymatically modified, building a new field of epitranscriptomics that is currently under intense interest. These modifications are reported in various physiological and pathological processes, which are reviewed brilliantly elsewhere, such as tRNA modifications in the role of development (Frye et al., 2018) and transcriptional and chromatin regulation by m^A (Wei & He, 2021) (Shi et al., 2019). Moreover, their respective RNA-modifying proteins (RMPs) are also the targets for the investigation of epitranscriptomic regulations (Shi et al., 2019). Specific to oncological research, these RNA-modifying processes are often hijacked in cancers to acquire pro-survival advantages, and aberrant epitranscriptomic modifications have been implicated in resistance to programmed cell death (PCD). Ferroptosis, a new type of PCD denoted by an iron-dependent lethal accumulation of lipid peroxides, has started to gain heed in recent years. The complexity in ferroptotic signaling has indeed offered more opportunities for potential therapeutic manipulations in treating cancer. We attempted to delineate the up-to-date discoveries on both epitranscriptomics and ferroptosis, bringing up the fundamentals to address any potential connection between the two. Next, we discussed whether a duologal relationship, or more, exists between the two, taking the ROS level and iron status into consideration. Lastly, we surveyed future perspectives that would favor the understanding of these topics.

Beyond transcriptomics: epitranscriptomics

RNA comprises several kinds of modifications on the transcripts that constitute the epitranscriptome. The enzyme-mediated covalent modifications on RNA, also termed epitranscriptomic modifications, experienced an arduous period after the pioneering discovery of pseudouridine (ψ) in 1951 by Davis and Ellen as the first epitranscriptomic modification (Davis & Allen, 1957). After the early work from Perry & Kelley, (1974) proving the existence of an mRNA epitranscriptomic modification in mouse L-cells, it has then...
become clearer that the life cycle of an mRNA transcript does not merely experience transcription but also posttranscriptional processing such as 5′-capping, polyadenylation, and most importantly in the context of this article, epitranscriptomic modifications.

Eptitranscriptomic modifications are observed in both coding mRNA transcripts (Frye et al., 2018) (Gilbert et al., 2016) and non-coding RNA, such as long non-coding RNA (IncRNA) (Yin et al., 2021), microRNA (miRNA) (Konno et al., 2019), and transfer RNA (tRNA) (Pereira et al., 2018). Dysregulated epitranscriptomic modifications on both coding mRNA and tRNA have been intuitively considered signatures in pathologies (Destefanis et al., 2021) (Suzuki, 2021) (Yang et al., 2020). Specifically, posttranscriptional editing determines the RNA fate through mediating cellular processes, including alternative splicing (Xue et al., 2021), nonsense-mediated mRNA decay (Li et al., 2019a), and translation (Ranjan & Leidel, 2019). Extending to biological functions, the epitranscriptome has built its niche in physiological regulation, which is exemplified by circadian rhythm regulation by A-to-I editing catalyzing the ADAR enzyme family (Terajima et al., 2017), GBM-associated protein expression upregulated by METTL3 via SOX2 (Visvanathan et al., 2018), and poor prognostic characterization through the IGF2BP/SOX2/METTL3 axis in CRC (Li et al., 2019b).
well-characterized ones, including N6-methyladenosine (m6A), N1-methyladenosine (m1A), and pseudouridine (Ψ). Others like 5-hydroxymethylcytosine (5-hmC), N4-acetylcytidine (ac4C), and adenosine-to-inosine editing (A-to-I) are only registered with unknown or unspecified functions. Moreover, MODOMICS covers the related diseases and pathways (Dunin-Horkawicz et al., 2006), with sequential updates at regular intervals (Machnicka et al., 2013) (Boccaletto et al., 2018), leading to more attention directed to the rising role of RNA modifications contributing to the nuanced transcriptomic homeostasis from clinicians and scientists (Song et al., 2020).

The fate of an mRNA transcript is determined by a series of events posttranscriptionally, and one of such crucial processes is epitranscriptomic modifications. In general, the process of mRNA epitranscriptomic editing relies on three major types of RNA-modifying proteins (RMPs):

1) writers that deposit RNA modifications, for e.g., methyltransferase-like (METTL) enzyme family members, zinc finger CCCH-type containing 13 (ZC3H13), and VIRMA/KIAA1429 for m6A, TRMT family members for m1A, ADARs for A-to-I editing, and NSUNs for m5C;

2) erasers that remove the epitranscriptomic modifications, for e.g., fat mass- and obesity-associated protein (FTO) for m6A and AlkB homologs (ALKBH) for m1A, m6A, and m5C;

3) readers that are recruited and recognize the modifications to alter the fate of mRNA transcripts, for e.g., YT521-B homology (YTH) domain family members for m6A and Aly/REF export factor (ALYREF) for m5C.

RNAWRE, which was constructed in 2020 by Nie et al. (2020) and apropos to mention, comprises more than 2000 manually curated writers, erasers, and readers. RMP regulation determines whether the previously mentioned epitranscriptomic signatures are installed, removed, or recognized. By dint of Table 1 summary and Figure 1 illustration, types of epitranscriptomic marks and their respective RMPs will not be outlined thoroughly in paragraphs. The concept of how these epitranscriptomic marks and RMP expression affect the existence and severity of ferroptosis will be discussed in later parts and illustrated in the compiled figures.

Detecting epitranscriptomics modifications

Even though the adjustments on nucleotides seem slight and miniscule, finding a way to elucidate the epitranscriptomic marks is never simple and uncomplicated. Consecutive efforts
are required owing to these nanoscopic modifications down to nucleotides. This review will not focus on the in-depth discussion of epitranscriptomic mark detection, given that such an issue has already been brilliantly reviewed elsewhere (Helm & Motorin, 2017) (Sarkar et al., 2021). Nevertheless, we shall highlight the important ones, including NGS-based techniques or mass spectrometry-based techniques.

Next-generation sequencing-based techniques

AlkB-facilitated RNA methylation sequencing (ARM-seq) (Cozen et al., 2015), combines reverse transcription (RT) and enzymatic demethylation and relies on detecting truncations due to existing methylated nucleosides during RT. Localization of truncations from high-throughput sequencing navigates the potential methylated sites in RNA transcripts, except when the reaction reaches RT-silent bases such as pseudouridine, ribothymidine, or mC. Aside from RT-methods, antibody-dependent assays like m6A-seq (for m6A) or m5A-seq (for m5A), MeRIP-seq (Dominissini et al., 2015), CLIP-based strategies (Ke et al., 2015), PAR-CLIP–MeRIP (Liu et al., 2015), miCLIP (for methylated nucleosides in RNA) (Hawley & Jaffrey, 2019), and suicide enzyme trap (for identification of methyltransferase targets on RNA strands) (Khooddami & Cairns, 2013) have also revolutionized the epitranscriptomic mark detection. By eliminating the possibility of having RT-arrest and mis-incorporation of nucleosides during RT like RT-based detection, enrichment-based methods stand out with their superb specificity to methylated nucleosides.

Mass spectrometry-based techniques

Dating back to 1977, McCloskey and Nishimura were the first to utilize MS to detect tRNA modifications down to nucleoside resolution. The RNA MS regimen relies on enzymatic digestion/reduction of RNA strands to nucleosides/nucleotides with the nucleic acid backbone being eliminated, and the downward workflow is analogous to metabolite MS, including ionizing the compound and detecting the molecule in an electric field, followed by a magnetic field. The determination of an m/z ratio greatly depends on retention time, molecular mass, and fragmentation patterns in tandem mass spectrometry (MS/MS) for the identification of modification residues (Helm & Motorin, 2017). Variations of MS include combination with liquid chromatography purification on RNA fragments a posteriori nucleases such as RNase T1 and MCI, followed by electrospray ionization (ESI) and MS/MS, entitled LC-ESI-MS/MS (Yuan, 2017). Two years ago, Wein et al. (2020) constructed an open-source database for documenting RNA MS data named NucleicAcidSearchEngine (NASE). Heiss et al. (2021) have also recreated LC-MS/MS by combining nucleic acid isotope labeling (NAIL) and MS, entitled NAIL-MS, to address the dynamic nature of epitranscriptomic modifications that the currently available MS protocols lack the ability to tackle. Nonetheless, despite the comprehensiveness offered by MS, respective localization of modifications in the RNA environment will be completely lost and irretrievable.

Ironing out the iron: investigating ferroptosis

The first observation on erastin-induced lethality in engineered Ras-mutant human foreskin fibroblasts discovered distinctive morphological features and biochemical machineries compared to traditional programmed cell death (PCD). Ferroptosis, coined in 2012 under the work of Dixon et al. (2012), has shed light on the field of PCD and has, henceforth, attracted heed from cell biologists. Devoid of apoptotic morphological features, such as apoptotic body formation or nuclear fragmentation, ferroptotic cells are characterized by increased mitochondrial densities and reduction of mitochondrial crista that are not observed in the conventional PCD (Li et al., 2020). The discovery of iron chelation also denoted an unprecedented biochemical pathway in regulating ferroptosis. Even so, much of our knowledge in ferroptosis is still not complete nor is satisfactory enough to intervene this mechanistic pathway in the current clinical settings.

In the history of ferroptosis characterization, the pioneering finding of erastin has led to the comprehensive dissection of ferroptosis in recent years. Large-scale screening experiments in surveying the killing effects of a multitude of compounds exerted on cancer cells via mitochondrial voltage-dependent anion channels, conducted by Dolma et al. (2003), have directed the very first discovery of erastin. Few years afterward, erastin treatment was investigated, and the results of lipid-related oxidative stress were noticed by Yagoda et al. (2007). The RAS-selective lethal 3 (RSL3) was brought up in 2008 from another large-scale synthetic lethal screening by Yang & Stockwell (2008) in the presence of RAS (therefore, the nomenclature). Dixon et al. (2012) officially entitled this iron-dependent cell death as “ferroptosis”. Successful characterization has then propagated more in-depth discoveries, including ferrostatin-1 (fer-1) inhibition of ferroptosis, mitochondria independency (Gaschler et al., 2018), sorafenib induction of ferroptosis (Lachaier et al., 2014) (Louandere et al., 2013), system X,− being inhibited by erastin (Dixon et al., 2014) (grounded in the fact that cysteine deprivation leads to glutathione-dependent cell death long before the characterization of ferroptosis (Eagle, 1955) (Hinson et al., 2010)), glutathione peroxidase 4 (GPX4) participation (Yang et al., 2014), and enormous regulatory ferroptotic inducers (other than erastin, e.g., DPIs, FIN56, and FINO2) and inhibitors (e.g., iron chelators, vitamin E, SRS8-24, and CA-1).
Delineating the mechanisms of ferroptosis

Ferroptosis starts with the production of lipid peroxides as a general cellular suicidal program with an iron-mediated oxidative mechanism. Cellular reactions exhibit redox equilibrium, and disruption of redox equilibrium is attributed to the synthesis and accumulation of reactive oxygen species. Definitive ROS, including superoxide anion (O$_2$–), hydrogen peroxide (H$_2$O$_2$), hydroxyl radicals (HO•), hydroperoxides (ROOH), and hydroxyl radicals (ROO•), are formed by partial reduction of oxygen. ROS are generated inevitably from oxidative phosphorylation in mitochondria to cellular respiration, and the endogenous antioxidant system is instrumental to remove the oxidative stress. It has been held as an axiom that ROS accumulation also lays the groundwork of multiple pathologies, given its roles in cellular damage in diabetic cardiomyopathy (Kaludercic & Di Lisa, 2020), atherosclerosis (Yang et al., 2017), neurological complications (Manoharan et al., 2016), and in cell growth, especially in cancers (Aggarwal et al., 2019)(Dias Amoedo et al., 2020)(Tien Kuo & Savaraj, 2006)(Zeng et al., 2021). A detailed mechanistic overview of ferroptosis is illustrated in Figure 2.

What lies at the cardiac part of this cellular iron-mediated killing is lipid ROS. The most abundant ROS, superoxide, is generated by cytochrome P450 and NADPH oxidases (NOXs) partial reduction, forming H$_2$O$_2$ by superoxide dismutase (SOD), and the anions proceed to the production of hydroxyl radicals with the catalytic role of iron. In fact, published articles only
documented the iron participation as the Fenton reaction, and the final Haber–Weiss reaction, obtained after balancing chemical equations from Fenton and the others, was less recognized than the Fenton reaction. Ferrous ions (Iron (II) or Fe^{2+}) are mainly produced from the labile iron pool (LIP) and upon radical attack to heme groups with iron–sulfur (Fe–S) clusters (Gomez et al., 2014). Oxidation of ferrous to ferric ion (iron (III) or Fe^{3+}) facilitates free radical formation from H_2O_2, whilst the O_2• radicals are also oxidized to harmless O_2 as a net Haber–Weiss reaction. Taken together, the iron-mediated production of hydroxyl radicals is a "superoxide-driven Fenton-catalyzing Haber–Weiss reaction," or Fenton/Haber–Weiss reaction, as illustrated in Figure 3.

After the Paleoproterozoic Great Oxygenation Event (GOE), lives on the earth were subjected to oxidation readily, especially for polyunsaturated lipids with bis-allylic carbons (Wagner et al., 1994). The victim of such ROS attack in ferroptosis after all the aforementioned series of events is, therefore, polyunsaturated fatty acids (PUFAs). Under normal physiology, PUFAs, including arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are situated in the cell membrane. The attack from accumulating free radicals to PUFAs, otherwise named peroxidation reaction, generates phospholipid free radicals (PL•) and, therefore, PUFA-containing-phospholipid hydroperoxides (PL-PUFA (PE)-OOH, PLOOH in short) (Forcina & Dixon, 2019), facilitated by different lipoxygenases (LOXs). It was also demonstrated that depletion of an acyl-CoA synthetase ACSL4 and LPCAT3 esterification enzyme inhibited ferroptosis (Doll et al., 2017) (Yuan et al., 2016). PLOOHs execute the unelucidated last hit to the cell membrane and initiate disruption to cellular integrity, leading to ferroptosis.

The transmembrane cysteine/glutamate exchanger commences the work to initiate a ferroptosis-specific antioxidant system. System x_c, which was found to be inhibited by erastin, serves as an amino acid homeostatic control with the exchange of extracellular L-cystine and intracellular L-glutamate. Dissecting the antiporter, it consists of two subunits, a light chain solute carrier family 7 member 11 (SLC7A11) and a heavy chain subunit SLC family 3 member 2 (SLC3A2), which are targeted by respective inhibitors. Intracellular cysteine from cystine reduction facilitates the production of glutathione (GSH) that is catalyzed by glutamate–cysteine ligase catalytic subunit (GCLC) (which is inhibited by buthionine sulfoximine (BSO)) and then by glutathione synthetase (GSS). The classical redox-associated glutathione system (GSH and oxidized GSH disulfide (GSSG)) comes in to play a role in antioxidant defense, proven back in the 90s (Ceballos-Picot et al., 1996). Glutathione peroxidase 4 (GPX4) protects the cells from ferroptotic death by reducing toxic PLOOHs to PUFA-containing-phospholipid hydroxides (PL-PUFA (PE)-OH, PLOH in short), with the presence of selenium (Liu et al., 2021) and GSH (Ursini & Maiorino, 2020). While PLOHs appear to be non-ferroptogenic (not ferroptosis-inducing), this marks the end of the brief ferroptosis mechanisms as the homeostasis is achieved.

Ferroptosis has been observed in different pathologies. For example, in Alzheimer’s disease that is characterized by prominent brain cell death, β-amyloid plaques and neurofibrillary tangles were investigated, and excess iron accumulation and downregulation of iron exporter, ferroportin1, were observed, thereby explaining the oxidative stress exerted and promoting the AD cognitive impairment (Bao et al., 2021). In renal ischemia/reperfusion injury (IRI), ferroptosis is proven in the mediation of renal tubule-synchronized necrosis, and a novel third-generation ferrostatin 16–86 could rescue or protect the tubular damage that contributes to IRI (Linkermann et al., 2014). In cancer, particularly in colorectal cancer, it was evident that ferroptosis promotes metabolic rewiring, or the Warburg effect, which favors cancer cell growth, as well as suppresses ferroptosis sensitivity by inducing ROS production and activating nuclear factor erythroid 2-related factor 2 (NRF2) (Yuan et al., 2021). These are just few examples that ferroptosis correlates with disease progression, and more details about various pathologies can be found in other good articles such as Jiang et al. (2021b) and Yan et al. (2021) for readers’ reference.

**Ferroptosis and epitranscriptomics: neither two monologues nor a mere duologue**

Due to technological advancements in investigating epitranscriptomics and firmer theoretical bedrock on the principle of ferroptosis, both topics are gaining escalating heed from scientists. However, the association between epitranscriptomics and ferroptosis has yet been organized. Thence, with reference to the preliminary background...
knowledge, we summarize some updates on ferroptosis and epitranscriptomic modifications in recent years and attempt to put a new perspective on the investigation of ferroptosis to facilitate the demystification of any connection between epitranscriptomics and ferroptosis.

**Feed-forward interaction: how do epitranscriptomics shape the niche of ferroptotic homeostasis?**

**Ferroptosis and m^6^A**

Being the most characterized epitranscriptomic modification, m^6^A has been widely investigated for its relationship with ferroptosis in different pathological phenomena, including cell cycle, drug resistance, biomarkers, or disease signatures. A couple of m^6^A writers, readers, and erasers have been focused to study as a direct or indirect target to mediate ferroptosis, sorted out in Table 2.

**Table 2: Discovered epitranscriptomic marks on ferroptosis-related proteins.**

| Disease model | Mechanisms in ferroptosis | Epitranscriptomic mark-associated protein | Discovery | Reference |
|---------------|---------------------------|------------------------------------------|-----------|-----------|
| Lung cells (A549) | Lipoxynegase pathway, arachidonic acid metabolic process, and response to selenium ion | m6A reader–YTHDF2 | BPQDs increase the global m6A level and decrease ALKBH5 to promote ferroptosis-related pathways | Ruan et al. (2021) |
| Acute myeloid leukemia cell line (TF-1) | GPX4 antioxidant | m6A eraser–FTO | In-house GNRa-CSP12 sensitized AML cells to TKIs by FTO–m^6^A hypomethylation on GPX4 to promote ferroptosis | Du et al. (2021) |
| Cardiomyocytes | Iron uptake ROS production | m^6^A writer–METTL14 | Doxorubicin induced METTL14 and IncRNA KCNQ1OT1 to inhibit miR-7-5p, triggering the TFRC increase to promote ferroptosis | Zhan et al. (2021) |
| Human hepatic malignant and normal cell lines | Cysteine import | m^6^A writer–METTL14, m^6^A reader–YTHDF2 | METTL14 suppression in SLC7A11 and thereafter degradation relied on the YTHDF2-dependent pathway were observed under hypoxia | Fan et al. (2021) |
| Malignant and normal lung cell lines | Cysteine import | m6A writer–METTL3, m6A reader–YTHDF1 | METTL3 modifies the m^6^A level in SLC7A11 by recruiting YTHDF1 to promote ferroptosis in LUAD. | Xu et al. (2021) |
| Human liver tissues | Cysteine import | m^6^A writer–METTL4, m6A reader–YTHDF1, m6A eraser–FTO | METTL4 upregulation and FTO downregulation increase global m^6^A level in BECN1 mRNA that originally inhibit SLC7A11, and the YTHDF1 increase promotes BECN1 stability to inhibit cysteine intake and promote ferroptosis in HSCs | Shen et al. (2021) |
| Mice HSCs | Cysteine import | m6A reader–YTHDF1, m6A eraser–FTO | DHA downregulated FTO to increase m^6^A in BECN1 mRNA, leading to YTHDF1-dependent enhanced stability to inhibit SLC7A11 cysteine-glutamate exchange, promoting HSC ferroptosis | Shen et al. (2022) |
| Human glioblastoma cell lines (U87MG and U251) | Cysteine import | m^6^A reader–NKAP | NKAP binds to m^6^A in SLC7A11 transcripts and promotes transcriptional splicing and maturation to suppress ferroptosis in glioblastoma cells | Sun et al. (2022) |
| CRC and adenoma tissues | Ferritinophagy | m6A eraser–ALKBH5 | CircRNA cIARS interacts with ALKBH5 to positively regulate ferritinophagy in SF-treated HCC cells | Liu et al. (2020) |
| BMSCs in mice | Erastin-induced ferroptotic cysteine transport | m^5^C writer–NSUN5 | NSUN5 downregulation is correlated with reduced m^5^C in FTH1/FTL, contributing to ferroptosis | Liu et al. (2022) |
| Human glioma cell line (U251) | Glutamine metabolism in the antioxidant system | A-to-I editing writer–ADAR | ATXN8OS was found to interact with ADAR and downstream interaction with ferroptosis-related targets is suspected to mediate ferroptosis. These targets include GLS2 | Luo et al. (2022) |
with the miR-7-5p and doxorubicin chemoresistance study carried out by Song et al. (2021) on exosomal miR-4443 and cisplatin resistance in non-small cell lung carcinoma. Tantamount to apoptosis, cisplatin simultaneously acts as a dual trigger of apoptosis and ferroptosis to kill cancer cells (Guo et al., 2018). On this groundwork, in tumoral and normal tissue-derived exosomes, their team discovered a distinctive expression level of miR-4443 between cisplatin-sensitive and cisplatin-resistant tissues and cell lines, and further functional and bioinformatics studies confirmed that m^6^A writer METTL3 was negatively regulated by miR-4443.

Further functional and bioinformatics studies con

bridging epitranscriptomics and ferroptosis was on m^5^C and its closely related work that is also one of the most recent discoveries. In bone marrow-derived mesenchymal stem cells (BMSCs), Liu's group reported a notable downregulation of NSUN5 in ferroptotic cells and unveiled the enhancement of Fe^2+^ ions in the m^6^A level on ferroptosis-suppressing protein 1 (FSP1), inhibiting its activity to suppress ferroptosis. Bioinformatics analyses on lncRNAs also revealed m^6^A regulators, namely, FMR1, HNRNPC, METTL16, METTL3, and METTL5, were expressed in higher levels than those in ferroptosis low-risk groups (Jiang, W. et al., 2021a). The aforementioned studies provided evidence that epitranscriptomics are phenomenally involved in ferroptotic disease models, particularly in drug-resistant cancers that have the characteristic to overcome cell death events. As ferroptosis is a new type of PCD, the participation of miRNA, IncRNA, or other types of RNA with distinguished epitranscriptomic features is worth investigating to obtain a complete picture of its disease progress contribution, in order to potentiate clinical relevance for disease manipulation in the future. The theoretical basis on how epitranscriptomics shaped the ferroptosis signaling was also exemplified in pan-cancer in vitro, including in hepatocellular carcinoma (Fan et al., 2021), hepatic stellate cells (Shen et al., 2022) (Shen et al., 2021), lung adenocarcinoma (Xu et al., 2022), and glioblastoma (Sun et al., 2022).

Ferroptosis and other epitranscriptomic marks

A majority of the published articles were m^6^A-based, and there is a huge lack of epitranscriptomic discoveries regarding other marks on ferroptosis. m^C^ is second to m^6^A in terms of the level being explored, and the investigation is still ongoing since we are only scratching the surface of the epitranscriptomic modifications aside from m^6^A (Liu et al., 2022). In fact, one closely related work that is also one of the most recent discoveries bridging epitranscriptomics and ferroptosis was on m^C^ and its exclusive writer NOP2/Sun RNA methyltransferase 5 (NSUN5). In bone marrow-derived mesenchymal stem cells (BMSCs), Liu's group reported a notable downregulation of NSUN5 in ferroptotic cells and unveiled the enhancement of Fe^2+^ ions in NSUN5 depletion in vitro. More importantly, NSUN5 overexpression, which was later confirmed as its methylating action on 5'UTR/3'UTR of ferritin heavy chain/light chain (FTH1/FTL), was correlated with TRAP1 recruitment on FTH1/FTL, a protein that governs the intracellular entry of iron ions, confirmed by LC-MS and co-immunoprecipitation (co-IP). Liu's group has impacted both the fields of ferroptosis and epitranscriptics by expanding the discussion to other base modifications other than the predominant m^6^A. Meanwhile, further studies on other disease or cell models, or more superior 3D culture and organoid models, necessitate to be carried out for proof-of-concept.

In addition to m^C^, in triple-negative breast cancer patients, investigating the tumor microenvironment (TME) guided the discovery of a rare epitranscriptomic feature that serves as a potential biomarker in microniches. Using spatial epitranscriptomic analyses on tumor microniches, Lee et al. (2022) sought to profile A-to-I editeome and identified high A-to-I editing in GPX4 variants in IF-stained tissues full-length transcriptome. This result fitted their hypothesis that cancer stem cells (CSCs) contain high A-to-I editing characteristic for their niche shaping, and the future validation work can potentiate the druggability of such epitranscriptomic feature in this ferroptotic-signaling protein.

Feedback interaction one: how will lipid ROS accumulation potentially influence the nuanced epitranscriptomic features back?

Cellular signaling in biological systems evolved with harmonized crosstalk and attempting to inspect the entirety via a single chronological representation remains laborious to reach the finality. It becomes interesting whether the accumulating lipid ROS being non-eliminated construct a feedback influence on the epitranscriptomic marks. Oxygen atoms in –OH groups and phosphodiester backbone are the most vulnerable to be subjected to chemical damage or oxidation (Liu et al., 2022), and ROS onslaught has demonstrated evidently in mutations (Niedernhofer et al., 2003), cell arrest (Dixon & Stockwell, 2014), and epitranscriptomic induction (Kumar & Mohapatra, 2021). Particularly in cancer, m^6^A induction has been studied and reviewed in response to the production of ROS, and a biphasic and conflicting effect on tumor growth, intriguingly, has been noticed (Chio & Tuveson, 2017) (Yang & Chen, 2021). The potential ROS effect in ferroptosis via epitranscriptomic mediation is hence plausible.

Since the concept of “global m^6^A level can be ROS-induced” was revealed, one ROS-induced post-translational regulation on m^6^A demethylase was discovered recently (Yu et al., 2021). In this study by Yu et al., human cell lines with high m^6^A induced by ROS and determined by m^6^A-seq, were employed to survey the intrinsic mechanism that contributed to the elevation, where SUMOylation in m^6^A demethylase ALKBH5 was found to be associated using comet analysis, a single-cell gel electrophoresis assay that helps determine DNA damage and repair equilibrium at a single cell level. Particularly, SUMOylation-deficiency in ALKBH5 led to weakened DNA repair in H_2_O_2-induced DNA damage, in other words, SUMOylation in ALKBH5 is essential in the increase of global m^6^A level by limiting the activity of m^6^A.
ers. As ROS also joins the ferroptotic signaling and can lead to ferroptotic cell death, how ROS can potentially construct a stressful environment and add on epitranscriptomic modifications of ferroptosis proteins remains to be extrapolated. Having a feedback loop discovered that thrusts in the cell death process offer a great potential to manipulate the pathways, and the prospects of targeting ferroptosis in therapeutic settings await.

**Feedback interaction two: how does iron imbalance contribute to an epitranscriptomic mark level?**

Dixon et al. (2012) extensively acknowledged the importance of iron in its mediation to the PCD event by coining the “ferro-” in the nomenclature of the iron-driven cell death, ferroptosis, assisted by the Nomenclature Committee of Cell Death (NCCD). Before then, prominent iron overload was observed among pathologies, such as hereditary hemochromatosis, along with the complications manifested, including organ damage, hypothyroidism, and hypogonadism. Managing iron homeostasis, thence, is necessitated from a medical standpoint, combined with the fact that ferroptosis is also dependent on intracellular iron status. In addition, *en route* to the research on how important iron to ferroptosis is, we also discovered some connections between iron and epitranscriptomic marks upon rummaging articles. We aimed to address the potential association of iron status and epitranscriptomics in ferroptosis and provided upcoming possible research directions to facilitate the elucidation of this mystery.

The fact that heme groups and Fe–S clusters are frequently under the attack of various kinds of ROS is well known (Imlay, 2006). This increases the intracellular level of Fe$^{2+}$ apart from the LIP, though the LIP serves as the predominant source of Fe$^{2+}$. In fact, perturbations of epitranscriptomics that affect the iron level or iron metabolism have been shown via some direct studies. In a hypopharyngeal squamous cell carcinoma (HPSCC) study by Ye et al. (2020), transcriptomic analyses including m$^A$-seq, RNA-seq, and RIP-seq identified m$^A$ reader YTHDF1’s downstream target transferrin receptor (TFRC), simultaneously linking to poor prognosis in postoperative platinum-based chemoradiotherapy (CCT) or radiation patients in an m$^A$-dependent manner. HPSCC patients with intratumorally elevated Fe$^{2+}$ were also shown upregulated YTHDF1 expression, and knockdown YTHDF1 in HPSCC cells proved the suppression of cell proliferation and migration ability. Taken together, as YTHDF1 modifies TFRC mRNA in cytosol and modulates transcriptomic stability and fate, relationships between an RMP and an iron metabolism participant were speculated by this pioneering work. Additionally, a pancreatic ductal adenocarcinoma (PDAC) study by Huang et al. (2021) aimed at elucidating the connection of ALKBH5 and iron metabolism, concretely on mRNAs encoding ubiquitin ligase FBXL5 and iron importers SLC25A28 and SLC25A37. ALKBH5 was identified to be mechanistically associated to the RNA decay event for FBXL5, and the team has divulged its unique prognostic ability among multiple m$^A$ regulators analyzed in the study. Considering FBXL5-IRP2 serves as the cardinal part to iron metabolism (Wang et al., 2020), this study adds on the evidence of connecting epitranscriptomic-mediated iron metabolism since the bridge between FBXL5 and ALKBH5 can now be surmised through transcriptomic analyses, and further validation work awaits to confirm.

**Prospect and unaddressed questions**

Yet, tracing back to the fact that excess intracellular iron leads to disturbed redox imbalance, and hence impaired cellular metabolism, we shall also pay heed to the crosstalk between iron metabolism and epitranscriptomics. Despite limited direct studies on the biological functions, some RMPs are reported to be affected by iron levels. m$^A$ demethylase ALKBH5 was Fe$^{2+}$-dependent, proven in an optimization research study for downstream screening work by Li et al. (2016). Therefore, it leaves us with the following questions on 1) how much iron level deviation intracellularly can drive impaired ALKBH5 function; 2) how much Fe$^{2+}$ perturbations can lead to redox imbalance, followed by the epitranscriptomic mark writing on RMPS that constitutes to a crosstalk signaling; and 3) what are the signaling paradigms required for iron-driven/ROS-induced epitranscriptomic mark writing and the potential involvement to ferroptosis. There are still many unsolved questions that build around the biological or biomedical conjectures on ferroptosis and epitranscriptomics that begin with iron imbalance and ROS induction. Addressing these outstanding questions shall help determine the direct involvement of distinct components in ferroptosis.

**Concluding remarks**

In retrospect, investigating a new topic in science has always been regarded as preposterous at the beginning, and the journey of vindication seems to be life-long and with collaborative efforts. Epitranscriptomics have indeed experienced a dejected period due to the lack of technological advancement, but the value *per se* is tantamount to epigenetic modifications owing to its importance in governing the ultimate phenotype of a gene. It is hard for us to ignore the participation of such element being pervasive on gene expression in ferroptosis, a new type of PCD discovered just in recent decades, and is still being explored for its potential clinical relevance. As the evidence regarding epitranscriptomics and ferroptosis began to pile up, with the associated indirect studies on the passengers of both, RMPs or lipid ROS, *videlicet*, we offered additional perspectives for readers.
to define the pathways of ferroptosis with respect to epitranscriptomic modifications, and thus to provide foreseeable opportunities toward comprehensiveness of such topics.

**Author contributions**

JC conceived and wrote the manuscript. GD, YD, and NW commented and provided expertise in ferroptosis. SN secured funding. YD and SN supervised the study and revised the manuscript.

**Funding**

This project was supported by research funds from the Lim Peng Suan Charitable Trust Research Fund and National Natural Science Foundation of China (81871900). This project was supported in part by the Hong Kong Research Grants Council Area of Excellence Scheme (Ref. AoE/M-401/20) and Research Impact Fund (Ref. R4017-18).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**References**

Aggarwal, V., Tuli, H. S., Varol, A., Thakral, F., Yerer, M. B., Sak, K., et al. (2019). Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements. *Biotechnology of Cancer* 9 (11), E735. doi:10.3390/biotechnolcancer.09035

Bao, W. D., Pang, P., Zhou, X. T., Hu, F., Xing, W., Chen, K., et al. (2021). Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease. *Cell Death Differ.* 28 (5), 1548–1562. doi:10.1038/s41418-020-00685-9

Becallotto, P., Machnicka, M. A., Purta, E., Pietkowski, P., Baginski, B., Wierckzi, T. K., et al. (2018). Modomics: A database of RNA modification pathways. 2017 update. *Nucleic Acids Res.* 46 (D1), D303–D307. doi:10.1093/nar/gkx1030

Ceballos-Picot, I., Witko-Sarsat, V., Merad-Boudia, M., Nguyen, A. T., Thevenin, M., Jaudson, M. C., et al. (1996). Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. *Free Radic. Biol. Med.* 21 (6), 845–855. doi:10.1016/S0891-5849(96)00223-x

Chao, I. I. C., and Tuveson, D. A. (2017). ROS in cancer: The burning question. *Trends Mol. Med.* 23 (5), 411–429. doi:10.1016/j.molmed.2017.03.004

Cozen, A. E., Quartley, E., Holmes, A. D., Habretta-Robinson, E., Philicky, E. M., and Lowe, T. M. (2015). ARM-Seq: ALKB-facilitated RNA methylation sequencing reveals a complex landscape of modified RNA fragments. *Nat. Methods* 12 (9), 879–884. doi:10.1038/nmeth.3508

Davis, F. F., and Allen, F. W. (1957). Ribonucleic acids from yeast which contain a fifth nucleotide. *J. Biol. Chem.* 227 (2), 907–915. doi:10.1016/s0021-9258(18)70770-9

Destaefanis, E., Avsar, G., Groza, P., Romitelli, A., Torrini, S., Pir, P., et al. (2021). A mark of disease: How mRNA modifications shape genetic and acquired pathologies. *Nature* 24 (7), 367–389. doi:10.1038/s41661-021-00721-120

Dias Amoedo, N., Dard, L., Sarlak, S., Mahfouf, W., Blanchard, W., Rousseau, B., et al. (2020). Targeting human lung adenocarcinoma with a suppressor of mitochondrial superoxide production. *Antioxid. Redox Signal.* 33 (3), 883–902. doi:10.1089/ars.2019.7892

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. *Cell* 149 (5), 1060–11072. doi:10.1016/j.cell.2012.03.042

Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., et al. (2014). Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *Elife* 3, e02523. doi:10.7554/elife.02523

Dixon, S. J., and Stockwell, B. R. (2014). The role of iron and reactive oxygen species in cell death. *Nat. Chem. Biol.* 10 (1), 9–17. doi:10.1038/nchembio.1416

Doll, S., Proneth, B., Tuyrina, Y. Y., Panzilis, E., Kobayashi, S., Ingold, L., et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nat. Chem. Biol.* 13 (1), 91–98. doi:10.1038/nchembio.2239

Dolma, S., Lessnick, S. L., Hahn, W. C., and Stockwell, B. R. (2003). Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. *Cancer Cell* 3 (3), 285–296. doi:10.1016/s1535-6108(03)00050-3

Dominissini, D., Moshtch-Moshkovitz, S., Amargiño, N., and Rechavi, G. (2015). Transcriptome-wide mapping of N⁶-Methyladenosine by m⁶A-seq. *Methods Enzymol.* 560, 131–147. doi:10.1016/bse.me.2013.03.001

Du, Y., Han, M., Cao, K., Li, Q., Pang, J., Dou, L., et al. (2021). Gold nanorods exhibit intrinsic therapeutic activity via controlling N⁶-methyladenosine-based epitranscriptomics in acute myeloid leukemia. *ACS Nano* 15, 17689–17704. doi:10.1021/acsnano.1c05547

Dunin-Horkawicz, S., Czarzaniec, A., Gajda, M. J., Feder, M., Grosjean, H., and Bujnicki, J. M. (2006). Modomics: A database of RNA modification pathways. *Nucleic Acids Res.* 34, D145–D149. doi:10.1093/nar/gkj084

Eagle, H. (1955). Nutrition needs of mammalian cells in tissue culture. *Science* 122 (3168), 501–514. doi:10.1126/science.122.3168.501

Fan, Z., Yang, G., Zhang, W., Liu, Q., Liu, G., Liu, P., et al. (2021). Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered VH1DF2-dependent silencing of SLC7A11. *J. Cell. Mol. Med.* 25 (10), 19179–19121. doi:10.1111/jcmm.16957

Focaina, G. C., and Dixon, S. J. (2019). GPX4 at the crossroads of lipid cation pathways. *Cell Death Differ.* 26 (5), 1034–1041. doi:10.1038/s41418-019-0225-3

Gilbert, W. V., Bell, T. A., and Schaeving, C. (2016). Messenger RNA modifications: Form, distribution, and function. *Science* 352 (6292), 1408–1412. doi:10.1126/science.aad7871

Gomez, M., Perez-Gallardo, R. V., Sanchez, L. A., Diaz-Perez, A. L., Cortes-Rojo, C., Meza Carmen, V., et al. (2014). Malfunctioning of the iron-sulfur cluster assembly machinery in Saccharomyces cerevisiae produces oxidative stress via
an iron-dependent mechanism, causing dysfunction in respiratory complexes. PLoS One 9 (10), e111585. doi:10.1371/journal.pone.0111585

Guo, J., Xu, B., Han, Q., Zhou, H., Xia, Y., Gong, C., et al. (2018). Ferroptosis: A novel anti-tumor action for cisplatin. Cancer Res. Treat. 50 (2), 445–460. doi:10.4145/crt.2016.572

Hawley, B. R., and Jaffrey, S. R. (2019). Transcriptome-wide mapping of m6A and m(6)A at single-nucleotide resolution using miCLIP. Curr. Protoc. Mol. Biol. 126 (1), e88. doi:10.1002/978-0-471-14342-5.978176-1374-0_18

Helm, M., and Motorin, Y. (2017). Detecting RNA modifications in the epitranscriptome: Predict and validate. Nat. Rev. Genet. 18 (5), 275–291. doi:10.1038/nr.2016.169

Hinson, J. A., Roberts, D. W., and James, L. P. (2010). Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. 196, 369–405. doi:10.1007/978-3-642-06636-0_12

Huang, R., Zhang, Z., Liu, X., Fei, Y., Tong, W. M., et al. (2021). RNA m(6)A demethylase ALKBH5 protects against pancreatic ductal adenocarcinoma. Cancer Res. Treat. 53, 608. doi:10.1158/0008-5472.CAN-18-119399. doi:10.1016/j.canret.2021.04.005

Luo, L., Dai, Q., Zheng, G., He, C., Parisien, M., and Pan, T. (2015). N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 518 (7540), 560–564. doi:10.1038/nature14234

Liu, J., Ren, Z., Yang, L., Zhu, L., Li, Y., Bie, C., et al. (2022). The NSUN5-FTH1/FTL pathway mediates ferroptosis in bone marrow-derived mesenchymal stem cells. Cell Death Dis. 8 (1), 99. doi:10.1038/s41419-022-00992-z

Liu, L., Wang, M., Gong, N., Tian, P., and Deng, H. (2021). Se improves GPX expression and SOD activity to alleviate heat-stress-induced ferroptosis-like death in goat mammary epithelial cells. Anim. Cells Syst. 25 (5), 283–295. doi:10.1007/s11987-021-12057-0

Luo, N., Dai, Q., Zheng, G., He, C., Parisien, M., and Pan, T. (2015). N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 518 (7540), 560–564. doi:10.1038/nature14234

Nie, F., Peng, P., Song, X., Wu, M., Tang, Q., and Chen, W. (2020). Rnawre: A resource of writers, readers and erasers of RNA modifications. Database 2020, baao49. doi:10.1093/database/baao49

Niedenhofer, I. L., Daniels, J. S., Rouzer, C. A., Greene, R. E., and Marnett, L. J. (2003). Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J. Biol. Chem. 278 (33), 31426–31433. doi:10.1074/jbc.M212549200

Perreira, M., Francisco, S., Varanda, A. S., Santos, M. Santos, M. A. S., and Soares, A. R. (2018). Impact of mRNA modifications and DNAmodify enzymes on proteostasis and human disease. Int. J. Mol. Sci. 19 (12), E3738. doi:10.3390/ijms19123738

Perry, R. P., and Derby, D. E. (1979). Existence of methylated messenger RNA in mouse I cells. Cell 17, 42–48. doi:10.1016/0092-8674(79)90153-6

Rana, A. K., and Anki, S. (2016). Reviving the RNA world: An insight into the RNA modifications as the two sides of the same coin? FEBS Lett. 593 (13), 1483–1493. doi:10.1002/1873-4685.13491

Ruan, F., Zeng, J., Yin, H., Jiang, S., Cao, X., Zheng, N., et al. (2021). RNA m6A modification alteration by black phosphorus quantum dots regulates cell ferroptosis: Implications for nanotoxicological assessment. Small Methods 5 (3), e2001345. doi:10.1002/smtd.202001345

Sarkar, A., Gasperi, W., Regley, U., Nevinis, S., Huber, S. M., Dedon, P. C., et al. (2012). Detecting the epitranscriptome. Wiley Interdiscip. Rev. RNA 12 (6), e1663. doi:10.1002/wrna.1663

Shen, M., Guo, M., Li, Y., Wang, Y., Qiu, Y., Shao, J., et al. (2022). m6A modification is required for dihydroorotaminase to alleviate liver fibrosis by inducing ferroptosis in hepatic stellate cells. Free Radic. Biol. Med. 182, 246–259. doi:10.1016/j.freeradbiomed.2022.02.028

Shen, M., Li, Y., Wang, Y., Shao, J., Zhang, F., Yin, G., et al. (2021). N(6)-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells. Redox Biol. 47, 102151. doi:10.1016/j.redox.2021.102151

Shi, H., Wei, J., and He, C. (2019). Where, when, and how: Context-dependent functions of RNA modification enzymes. Mol. Cell 74 (4), 640–650. doi:10.1016/j.molcel.2019.04.025

Song, H., Liu, D., Song, S., Zeng, L., Wu, Z., Zhao, P., et al. (2020). Epitranscriptomics and epitoeroxins in cancer drug resistance: Therapeutic implications. Signal Transduct. Target. Ther. 5 (1), 193. doi:10.1038/s41392-020-00390-w

Song, Z., Jia, G., Ma, P., and Cang, S. (2021). Exosomal m6R4443 promotes cisplatin resistance in non-small cell lung cancer by regulating FSP1 m6A modification-mediated ferroptosis. Life Sci. 217, 119399. doi:10.1016/j.lfs.2021.119399
SLC7A11 mRNA splicing in an m(6)A-dependent manner. Cell Death Dis. 13 (1), 73. doi:10.1038/s41419-022-04524-2

Suzuki, T. (2021). The expanding world of RNA modifications and their disease relevance. Nat. Rev. Mol. Cell Biol. 22 (6), 375–392. doi:10.1038/s41580-021-00342-0

Terajima, H., Yoshitane, H., Ozaki, H., Suzuki, Y., Shimb, S., Kuroda, S., et al. (2017). ADAR1B catalyzes circadian A-to-I editing and regulates RNA rhythm. Nat. Genet. 49 (1), 146–151. doi:10.1038/ng.3731

Tien Kuo, M., and Savaraj, N. (2006). Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol. Carcinog. 45 (9), 701–709. doi:10.1002/mc.20240

Ursini, F., and Maiorino, M. (2020). Lipid peroxidation and ferroptosis: The role of GSH and GPX4. Free Radiac. Biol. Med. 152, 175–185. doi:10.1016/j.freeradbiomed.2020.02.027

Vivianathan, A., Patil, V., Arora, A., Hegde, A. S., Arivazhagan, A., Santosh, V., et al. (2018). Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene 37 (4), 522–533. doi:10.1038/onc.2017.351

Wagner, R. A., Buettner, G. R., and Burns, C. P. (1994). Free radical-mediated lipid peroxidation in cells: Oxidizability is a function of cell lipid bis-allylic hydrogen content. Biochemistry 33 (15), 4449–4453. doi:10.1021/bi00181a003

Wang, H., Shi, H., Rajan, M., Canaris, E. R., Hong, S., Simoneschi, D., et al. (2020). FBXL5 regulates IRP2 stability in iron homeostasis via an oxygen-responsive [2Fe2S] cluster. Mol. Cell 78 (1), 31–41. doi:10.1016/j.molcel.2020.02.011

Wei, J., and He, C. (2021). Chromatin and transcriptional regulation by reversible RNA methylation. Curr. Opan. Cell Biol. 70, 109–115. doi:10.1016/j.cceb.2020.11.005

Wein, S., Andrews, B., Sachsenberg, T., Santos-Rosa, H., Kohlbacher, O., Kouzarides, T., et al. (2020). A computational platform for high-throughput analysis of RNA sequences and modifications by mass spectrometry. Nat. Commun. 11 (1), 926. doi:10.1038/s41467-020-14665-7

Xu, Y., Lv, D., Yan, C., Su, H., Zhang, X., Shi, Y., et al. (2022). METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 mRNA modification. Cancer Cell Int. 22 (1), 11. doi:10.1186/s12935-021-0243-6

Xue, C., Zhao, Y., Li, G., and Li, L. (2021). Multi-omic analyses of the (m5)C regulator ALYREF reveal its essential roles in hepatocellular carcinoma. Front. Oncol. 11, 633415. doi:10.3389/fonc.2021.633415

Yagoda, N., von Rechenberg, M., Zagajor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., et al. (2007). RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447 (7146), 864–868. doi:10.1038/nature05859

Yang, H. F., Zou, T., Yao, Q. Z., Xu, S., Li, H., Beladi, A. A., et al. (2021). Ferroptosis: Mechanisms and links with diseases. Signal Transduct. Target. Ther. 6 (1), 49. doi:10.1038/s41392-020-00428-9

Yang, B., and Chen, Q. (2021). Cross-talk between oxidative stress and m(6)A RNA methylation in cancer. Oxid. Med. Cell. Longev. 2021, 6547528. doi:10.1155/2021/6547528

Yang, W. S., Srilamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Visvanathan, V., et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (1-2), 317–331. doi:10.1016/j.cell.2013.12.010

Yang, W. S., and Stockwell, B. R. (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS harboring cancer cells. Chem. Biol. 15 (3), 234–245. doi:10.1016/j.chembiol.2008.02.010

Yang, X., Xu, H., Liu, J., Wang, R., Zhang, C., Han, F., et al. (2020). N6-methyladenine modification in noncoding RNAs and its function in cancer. Biomark. Res. 8 (1), 61. doi:10.1186/s40364-020-00244-x

Yang, X., Li, Y., Li, Y., Ren, X., Zhang, H., Xu, D., et al. (2017). Oxidative stress-mediated atherosclerosis: Mechanisms and therapies. Front. Physiol. 8, 600. doi:10.3389/fphys.2017.00600

Ye, J., Wang, Z., Chen, X., Jiang, X., Dong, Z., Hu, S., et al. (2020). YTHDF1-enhanced iron metabolism depends on TFRC m(6)A methylation. Theranostics 10 (26), 12072–12089. doi:10.7150/thno.51231

Yin, L., Zhu, X., Novak, P., Zhou, L., Gao, L., Yang, M., et al. (2021). The epitranscriptome of long noncoding RNAs in metabolic diseases. Clin. Chem. Acta. 515, 80–89. doi:10.1016/j.cca.2021.01.001

Yu, F., Wei, J., Cui, X., Yu, C., Ni, W., Bungert, J., et al. (2021). Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res. 49 (10), 5779–5797. doi:10.1093/nar/gka415

Yuan, B. F. (2017). Liquid chromatography-mass spectrometry for analysis of RNA adenosine methylation. Methods Mol. Biol. 1562, 33–43. doi:10.1007/978-1-4939-6807-7_3

Yuan, H., Li, X., Zhang, X., Kang, R., and Tang, D. (2016). Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun. 478 (3), 1338–1343. doi:10.1016/j.bbrc.2016.08.124

Yuan, Y., Ni, S., Zhuge, A., Li, B., and Li, L. (2021). Iron regulates the Warburg effect and ferroptosis in colorectal cancer. Front. Oncol. 11, 614778. doi:10.3389/fonc.2021.614778

Zeng, J., Li, M., Xu, J. Y., Xiao, H., Yang, X., Fan, J. X., et al. (2021). Aberrant ROS mediate cell cycle and motility in colorectal cancer cells through an oncogenic CXCL14 signaling pathway. Front. Pharmacol. 12, 764015. doi:10.3389/fphar.2021.764015

Zhuang, S., Ma, Y., Zeng, Y., Lu, C., Yang, F., Jiang, N., et al. (2021). METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis. Cell Biol. Toxicol. doi:10.1007/s10565-021-09660-7

Cheung et al. 10.3389/fcell.2022.982606